As we know, specific blockade of the PD-1/PD-L1 inhibitory pathway is one of the most important strategies for targeted therapy of HCC, and the basis for the implementation of this therapeutic strategy is the infiltration of immune cells in tumor tissues (Waidmann, 2018). Here, CD274 is linked to neoplasm.